Inclusion Criteria (Based on CARE-MS-II3, guidelines and Rio-criteria for treatment failure):  Written informed consent and agreement to comply to study protocol Age: 18-55 years EDSS: 0.0 - 6.0 RRMS according to McDonald 2010 < 10 years of disease course after symptom onset Active disease with one of the following treatment failures occur-ring not earlier than 6 months after initiation of an approved DMT 2 or more relapses within the last 12 months  or  1 relapse within the last 12 months and a Gd-enhancing lesion on MRI > 3 mm > 3 months before or after relapse onset or 2 new T2-lesions  or  On-going signs of MRI activity in the last 6 months (either Gd-en-hancing of ≥ 3 mm lesion at any exam in the last year; or more than 5 new T2 lesions (≥ 3 mm)  or  Patients stable under natalizumab but who have to stop treatment due to an increasing PML risk are defined as active, if a MRI within 6 months after termination of natalizumab shows new T2 or Gd-enhancing lesions and at least one other treatment fail-ure prior to natalizumab is documented.  Exclusion Criteria:  Secondary or primary progressive MS Pregnancy, or other medical condition incompatible with aHSCT Any treatment or medical condition that, according to the haematologist / transplant specialist precludes the use of aHSCT John Cunningham virus (JCV) antibody index of > 1.5 in previ-ously natalizumab-treated patients, if a negative CSF JCV-PCR prior to screening is not available Relapse during 30 days before initiation of treatment. If a relapse occurs during this period and eligibility criteria are otherwise ful-filled, start of treatment will be delayed until at least 30 days after receiving steroids.  Concurrent clinically significant (as determined by the investiga-tors and haematologist / transplant specialist) cardiac, immuno-logical, pulmonary, neurological, renal or other major disease such as:  Prominent cardial disease (Left ventricular ejection frac-tion (LVEF) < 40%, myocardial infarction or ischemia, un-controlled arrhythmias, pericardial effusion > 1 cm) Cerebrovascular disease Renal disease (creatinine clearance < 30 ml/min/m2) Respiratory disease (DLCO < 40% predicted) Active bleeding or clotting disease History of human immunodeficiency virus (HIV) or posi-tive HIV antibody testing Any uncontrolled acute or chronic infection, including HIV, hepatitis B surface antigen positivity and hepatitis C PCR positivity Cancer except in situ cervix or cutaneous Unwillingness or inability to comply with the requirements of this protocol including the presence of any condition (physical, men-tal, or social) that is likely to affect the patient returning for follow-up visits on schedule. Unwillingness to use contraception. Previous participation in this study, previous treatment with aHSCT or already both comparators  Ongoing immunotherapy. Treatment with interferon or glati-rameracetate will need no wash-out. Treatment pause before oc-relizumab/alemtuzumab or aHSCT will be:  for dimethylfumarate and fingolimod: 8 weeks for natalizumab: 8 weeks for ocrelizumab: 12 weeks for alemtuzumab: 12 months for teriflunomide: 4 weeks after elimination with cholesty-ramine for cladribine: 24 weeks Patients with cognitive impairments who are unable to provide written, informed consent prior to any testing under this protocol, including screening and baseline investigations that are not con-sidered part of routine patient care.